For this reason, human CD141+ DCs generated from CD34+ hematopoietic stem cells (HSCs), as conventional type 1 DCs (cDC1s), have been extensively studied in the development of DC-based therapies against cancer14,15; however, whether CD141+ DC therapies are effective in ovarian cancer remains unknown. This evidence concerns the gene THBD and ovarian carcinoma.